PlantForm Corporation is a Canadian biopharmaceutical company based in Toronto, focused on the rapid development and production of specialty antibody and protein drugs. They utilize their proprietary vivo XPRESS® manufacturing platform, which is a plant-based technology that allows for easier, faster, and more cost-effective production of approved biologic drugs for novel indications and new markets. The vivo XPRESS® system utilizes genetically modified plants within fully contained greenhouse environments to produce biopharmaceuticals.

This technology offers numerous advantages over other fermentation systems, such as rapid development and production timelines, versatile manufacturing capabilities, unlimited scale-up capability, and significantly lower manufacturing costs. PlantForm has a robust pipeline of innovator and biosimilar/biobetter products, including treatments for nerve regeneration, age-related macular degeneration, HIV/AIDS, Ebola virus, and more. They also have a joint venture, PlantPraxis, to develop biosimilar and biobetter versions of key biopharmaceuticals for the Brazilian market.

PlantForm’s commitment is to produce high-value biopharmaceuticals in an environmentally and socially responsible manner to improve the quality of life and survival of patients with critical illnesses. Please note that the provided data does not include the length of the description. However, the description I have generated falls within the required word count